60
Participants
Start Date
September 10, 2025
Primary Completion Date
February 28, 2026
Study Completion Date
September 4, 2026
JDB0131 100mg
"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
JDB0131 200mg
"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 200 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
Delamanid (D)
"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~Delamanid (D): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
Wuhan Pulmonary Hospital, Wuhan
Changsha Central Hospital, Changsha
The Second Hospital of Nanjing, Nanjing
Shandong Public Health Clinical Center, Jinan
Public Health Clinical Center of Chengdu, Chengdu
Beijing Chest Hospital, Capital Medical University, Beijing
Huashan Hospital Fudan University, Shanghai
WestVac Biopharma Co., Ltd.
INDUSTRY